Holen Sie sich die Stockscreener-App
9.62
5.37%
0.49
Vorhandelsmarkt:
10.00
0.38
+3.95%
Schlusskurs vom Vortag:
$9.13
Offen:
$9.23
24-Stunden-Volumen:
296.06K
Relative Volume:
0.88
Marktkapitalisierung:
$192.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-52.07M
KGV:
-46.32
EPS:
-0.2077
Netto-Cashflow:
$-44.93M
1W Leistung:
+8.95%
1M Leistung:
+0.10%
6M Leistung:
-15.59%
1J Leistung:
-30.83%
1-Tages-Spanne:
$8.96
$9.62
1-Wochen-Bereich:
$8.83
$9.62
52-Wochen-Spanne:
$6.50
$19.85
Cybin Inc Stock (CYBN) Company Profile
Firmenname
Cybin Inc
Sektor
Branche
Telefon
908 764 8385
Adresse
100 King Street West, Suite 5600, Toronto
Vergleichen Sie CYBN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
9.62 | 192.33M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-11-19 | Herabstufung | Maxim Group | Buy → Hold |
Cybin Inc Aktie (CYBN) Neueste Nachrichten
(CYBN) Trading Signals - Stock Traders Daily
Cybin Inc: Paradigm Changing Ambitions (NYSE:CYBN) - Seeking Alpha
Cybin enters partnership agreement to conduct phase 3 trial for depression candidate - MSN
Cybin Partners with Segal Trials for Pivotal Phase 3 Program - TipRanks
Cybin launches phase 3 trial for depression treatment - Investing.com India
Cybin launches clinical site partnerships to support PARADIGM program - TipRanks
Cybin Launches Strategic Clinical Site Partnerships to Support Paradigm, A Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder - Marketscreener.com
Thinking about buying stock in Hanryu Holdings, Absci Corp, Spero Therapeutics, BioXcel Therapeutics, or Cybin? - Marketscreener.com
Occidental Petroleum Corp (OXY-N) QuotePress Release - The Globe and Mail
Cybin Inc. Achieves Breakthroughs in Mental Health Treatment - TipRanks
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025 - Financial Post
Jane Street Group LLC Has $204,000 Stake in Cybin Inc. (NYSE:CYBN) - Defense World
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - BioSpace
Cybin CEO to Present at Lytham Partners Healthcare Summit: Mental Health Innovation Spotlight - StockTitan
Cybin (OTCMKTS:CLXPF) Trading 5.4% Higher – Time to Buy? - Defense World
BUSINESS WIRE NEWS RELEASES - Wallaceburg Courier Press
Cybin (OTCMKTS:CYBN) Trading Down 2% – Here’s What Happened - Defense World
Learn to Evaluate (CYBN) using the Charts - Stock Traders Daily
Cybin (NYSE:CYBN) Stock Price Up 1%Here's Why - MarketBeat
Objective long/short (CYBN) Report - Stock Traders Daily
Cybin (FRA:R7E) Total Inventories : €0.00 Mil (As of Sep. 2024) - GuruFocus.com
Facet Life Sciences Partners with Cybin to Advance Mental Health Therapies - MSN
Cybin Reveals Promising Results in Depression Treatment - TipRanks
Cybin's Breakthrough Clinical Data Shows 100% Response Rate in Depression Treatment Study - StockTitan
(CYBN) Investment Report - Stock Traders Daily
PEAK6 Investments LLC Sells 420,512 Shares of Cybin Inc. (NYSE:CYBN) - MarketBeat
Cybin Stock In Focus On MDD Treatment's 'Breakthrough’ Efficacy: Retail Turns Extremely Bullish - MSN
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024 - Chatham-Kent This Week
Cybin to Discuss Breakthrough Treatments at Fireside Chat - TipRanks
TANG CAPITAL MANAGEMENT LLC Increases Stake in Cybin Inc - GuruFocus.com
Psychedelic Drugs Market Growth in Future Scope 2024-2031 | - openPR
Cybin (FRA:R7E) 3-Year EPS without NRI Growth Rate : 6.10% (As of Sep. 2024) - GuruFocus.com
Cybin (FRA:R7E) 50-Day SMA : €9.05 (As of Nov. 30, 2024) - GuruFocus.com
Cybin (OTCMKTS:CYBN) Stock Price Down 4.3%What's Next? - MarketBeat
FDA's Psychedelic Reckoning - Life Science Leader Magazine
Cybin (STU:R7E) Earnings Yield (Joel Greenblatt) % : -151.52% (As of Sep. 2024) - GuruFocus.com
Cybin Inc. Advances in Mental Health Treatments - TipRanks
Cybin (STU:R7E) Change In Receivables : €-1.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
What is Bloom Burton's Estimate for Cybin FY2025 Earnings? - MarketBeat
HC Wainwright Brokers Decrease Earnings Estimates for Cybin - MarketBeat
Cybin launches new program phase to treat Major Depressive Disorder - MSN
Breakthrough Therapy Shows Promising Long-Term Results for Depression - Streetwise Reports
Cybin’s Breakthrough: Psychedelic Depression Drug CYB003 Sustains 12-Month Symptom Remission in Major Depressive Disorder - geneonline
H.C. Wainwright reiterates Buy on Cybin stock, sees strong potential for CYB003 in MDD - Investing.com
Cybin reports sustained depression treatment effects By Investing.com - Investing.com Canada
Cybin (NYSE:CYBN) Receives Buy Rating from HC Wainwright - MarketBeat
Cybin Reports Positive Phase 2 Data for CYB003 - The Dales Report
Cybin’s CYB003 Shows Promising Results for Depression - TipRanks
Cybin reports sustained depression treatment effects - Investing.com
Finanzdaten der Cybin Inc-Aktie (CYBN)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
Kapitalisierung:
|
Volumen (24h):